Publications

1. Schubauer-Berigan MK, Madia F, Kunzmann AT, Benbrahim-Tallaa L, de Conti A, Facchin C, et al. (2026). Progress in identifying the preventable causes of human cancer: the experience of the IARC Monographs program. J Natl Cancer Inst Monogr. 2026(72):78–85. https://doi.org/10.1093/jncimonographs/lgaf039 PMID:42008728
2. de Conti A, Madia F, Schubauer-Berigan MK, Benbrahim-Tallaa L (2025). Carcinogenicity of some metals evaluated by the IARC Monographs: a synopsis of the evaluations of arsenic, cadmium, cobalt, and antimony. Toxicol Appl Pharmacol. 504:117506. https://doi.org/10.1016/j.taap.2025.117506 PMID:40780533
3. Berrington de Gonzalez A, Gunter MJ, Schubauer-Berigan MK, Garcia-Closas M (2026). The multi-dimensional role of cancer epidemiology in cancer prevention: discovery science and beyond. J Natl Cancer Inst. 118(1):18–25. https://doi.org/10.1093/jnci/djaf200 PMID:40737505
4. Turner MC, Basagaña X, Albin M, Broberg K, Burdorf A, van Daalen KR, et al. (2025). Occupational health in the era of climate change and the green transition: a call for research. Lancet Reg Health Eur. 54:101353. https://doi.org/10.1016/j.lanepe.2025.101353 PMID:40613104
5. DeMarini DM, Gwinn W, Watkins E, Reisfeld B, Chiu WA, Zeise L, et al. (2025). IARC workshop on the key characteristics of carcinogens: assessment of endpoints for evaluating mechanistic evidence of carcinogenic hazards. Environ Health Perspect. 133(2):25001. https://doi.org/10.1289/EHP15389 PMID:39899356
6. Berrington de González A, Masten SA, Bhatti P, Fortner RT, Peters S, Santonen T, et al. (2024). Advisory Group recommendations on priorities for the IARC Monographs. Lancet Oncol. 25(5):546–8. https://doi.org/10.1016/S1470-2045(24)00208-0 PMID:38621402
7. Middleton DRS, Wedekind R, Hall AL, Suonio E, DeBono N, Vermeulen R, et al. (2024). Critical reviews of exposure assessment in carcinogenic hazard identification: the IARC Monographs experience. Occup Environ Med. 81(7):366–72. https://doi.org/10.1136/oemed-2023-109277 PMID:39033030
8. Turner MC, Cogliano V, Guyton K, Madia F, Straif K, Ward EM, et al. (2023). Research recommendations for selected IARC-classified agents: impact and lessons learned. Environ Health Perspect. 131(10):105001. https://doi.org/10.1289/EHP12547 PMID:37902675
9. Hasserjian RP, Khoury JD, Bueso-Ramos C, Dirnhofer S, Lokuhetty D, Ponzoni M (2026). Advancing the classification of hematolymphoid neoplasms together: for patients, medicine, and science. Blood. 147(9):915–9. https://doi.org/10.1182/blood.2025030689 PMID:41481391
10. Hodge JC, Netto GJ, Rekhi B, Cooper WA, Eden M, Field AS, et al. (2025). WHO Classification of Tumours: evolution of a global resource in the molecular era. Lancet Oncol. 26(4):410–3. https://doi.org/10.1016/S1470-2045(24)00709-5 PMID:40179904
11. Cree IA, Arends MJ, Khoury JD, Denton ERE, Gill AJ, Lazar AJ, et al. (2026). The WHO Classification of Genetic Tumour Syndromes: considerations for histopathology. Histopathology. 88(7):1291–4. https://doi.org/10.1111/his.70139 PMID:41852243
12. Quinn C, Tan PH, Allison KH, Brogi E, Lakhani SR, Schnitt SJ, et al.; WCT Standing Editorial Board (2026). World Health Organization classification of tumours of the breast 6th edition 2026. Histopathology. his.70149. https://doi.org/10.1111/his.70149 PMID:42011085
13. Wijesinghe H, Puspanathan P, Giesen C, Indave Ruiz BI, Krpelanova E, Rous B, et al. (2026). Impact of WHO Classification of Tumours on cancer prevention, diagnosis, research, public health, and economics. J Natl Cancer Inst Monogr. 2026(72):86–94. https://doi.org/10.1093/jncimonographs/lgaf043 PMID:42008733
14. Arends MJ, Esposito I, Gill AJ, Hruban RH, Khoury JD, Kojima M, et al.; WCT Standing Editorial Board (2026). Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system. Histopathology. 88(7):1295–314. https://doi.org/10.1111/his.70116 PMID:41724188
15. Colling R, Indave I, Del Aguilla J, Cierco Jimenez R, Campbell F, Chechlińska M, et al. (2024). Moving forward on tumor pathology research reporting: a guide for pathologists from the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 37(7):100515. https://doi.org/10.1016/j.modpat.2024.100515 PMID:38763419
16. Gapstur SM, Mariosa D, Neamtiu L, Nethan ST, Rehm J, Huckle T, et al. (2025). The IARC perspective on the effects of policies on reducing alcohol consumption. N Engl J Med. 392(17):1752–9. https://doi.org/10.1056/NEJMsr2413289 PMID:40305721
17. Lauby-Secretan B (2025). Response to the current perspective: evaluation of screening mammography effectiveness: the IARC recommendations of 2015 need revision. Eur J Cancer. 226:115658. https://doi.org/10.1016/j.ejca.2025.115658 PMID:40729841
18. Rumgay H, Colombet M, Ramos da Cunha A, Filho AM, Warnakulasuriya S, Conway DI, et al. (2026). Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022. CA Cancer J Clin. 76(1):caac.70048. https://doi.org/10.3322/caac.70048 PMID:41335400
19. Mariano LC, Warnakulasuriya S, Lauby-Secretan B, Monteiro L (2026). Investigating the association between oral hygiene and oral cancer: a systematic review and meta-analysis. Oral Dis. odi.70201. https://doi.org/10.1111/odi.70201 PMID:41840681
20. Nethan ST, Pérez-de-Oliveira ME, Campbell F, Santos-Silva AR, Lauby-Secretan B (2026). Interventions for oral cancer prevention: an evidence and gap map. Int J Cancer. 159(1):188–97. https://doi.org/10.1002/ijc.70391 PMID:41730778